Pressemitteilungen

MediGene AG (Frankfurt: MDG, Prime Standard, TecDAX) announces that Dr. Peter Heinrich, CEO and Chairman of the Executive Board of MediGene AG, has resigned from his position as member of the Executive Board with immediate effect. The Supervisory Board of MediGene AG has accepted the resignation and has appointed Dr. Frank Mathias, until now Chief Operating Officer of MediGene AG, as Chairman of the Executive Board of MediGene AG.

This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene® is a registered trademark of MediGene AG. This trademark may be owned or licensed in select locations only.

- Ende –

Die MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG, TecDAX) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies. MediGene has several drug candidates in clinical development, including EndoTAG™-1, which could offer substantial sales returns. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treaTMent of cancer and autoimmune diseases.